ABCL
Price
$11.38
Change
-$0.85 (-6.94%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
3.97B
18 days until earnings call
Intraday BUY SELL Signals
LGND
Price
$307.72
Change
-$7.06 (-2.24%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
6.28B
7 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ABCL vs LGND

ABCL vs LGND Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABCL vs. LGND commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABCL is a Hold and LGND is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABCL with price predictions
Oct 21, 2026

ABCL in downward trend: price may decline as a result of having broken its higher Bollinger Band on September 29, 2026

ABCL broke above its upper Bollinger Band on September 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 40 similar instances where the stock broke above the upper band. In 37 of the 40 cases the stock fell afterwards. This puts the odds of success at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for ABCL moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 30 similar instances where the indicator moved out of overbought territory. In 25 of the 30 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.

The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABCL as a result. In 75 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for ABCL turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 33 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

ABCL moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +5.12% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABCL advanced for three days, in 204 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 128 of 165 cases where ABCL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.427) is normal, around the industry mean (2.988). P/E Ratio (-22.667) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (53.191) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ABCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for LGND with price predictions
Oct 21, 2026

LGND in upward trend: 10-day moving average crossed above 50-day moving average on September 28, 2026

The 10-day moving average for LGND crossed bullishly above the 50-day moving average on September 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on LGND as a result. In 69 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for LGND just turned positive on October 21, 2026. Looking at past instances where LGND's MACD turned positive, the stock continued to rise in 32 of 49 cases over the following month. The odds of a continued upward trend are 65%.

LGND moved above its 50-day moving average on September 22, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +5.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where LGND advanced for three days, in 258 of 338 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The 10-day RSI Indicator for LGND moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 43 similar instances where the indicator moved out of overbought territory. In 26 of the 43 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LGND declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

LGND broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for LGND entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. LGND’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.486) is normal, around the industry mean (2.988). P/E Ratio (31.013) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (1.267) is also within normal values, averaging (9.059). Dividend Yield (0.006) settles around the average of (123.903) among similar stocks. P/S Ratio (20.325) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

FUNDAMENTALS RATINGS
ABCL vs LGND: Fundamental Ratings
ABCL
LGND
OUTLOOK RATING
1..100
7038
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
91
Overvalued
PROFIT vs RISK RATING
1..100
1004
SMR RATING
1..100
9444
PRICE GROWTH RATING
1..100
3438
P/E GROWTH RATING
1..100
9794
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ABCL's Valuation (9) in the null industry is significantly better than the same rating for LGND (91) in the Biotechnology industry. This means that ABCL’s stock grew significantly faster than LGND’s over the last 12 months.

LGND's Profit vs Risk Rating (4) in the Biotechnology industry is significantly better than the same rating for ABCL (100) in the null industry. This means that LGND’s stock grew significantly faster than ABCL’s over the last 12 months.

LGND's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for ABCL (94) in the null industry. This means that LGND’s stock grew somewhat faster than ABCL’s over the last 12 months.

ABCL's Price Growth Rating (34) in the null industry is in the same range as LGND (38) in the Biotechnology industry. This means that ABCL’s stock grew similarly to LGND’s over the last 12 months.

LGND's P/E Growth Rating (94) in the Biotechnology industry is in the same range as ABCL (97) in the null industry. This means that LGND’s stock grew similarly to ABCL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABCLLGND
RSI
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
62%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
65%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 9 days ago
82%
Bearish Trend 9 days ago
68%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
66%
Aroon
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
61%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (ABCL: $12.24 vs. LGND: $314.78)
Brand notoriety: ABCL and LGND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABCL: 62% vs. LGND: 70%
Market capitalization -- ABCL: $3.68B vs. LGND: $6.14B
ABCL [@Biotechnology] is valued at $3.68B. LGND’s [@Biotechnology] market capitalization is $6.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABCL’s FA Score shows that 1 FA rating(s) are green while LGND’s FA Score has 1 green FA rating(s).

  • ABCL’s FA Score: 1 green, 4 red.
  • LGND’s FA Score: 1 green, 4 red.
According to our system of comparison, LGND is a better buy in the long-term than ABCL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABCL’s TA Score shows that 4 TA indicator(s) are bullish while LGND’s TA Score has 5 bullish TA indicator(s).

  • ABCL’s TA Score: 4 bullish, 5 bearish.
  • LGND’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, LGND is a better buy in the short-term than ABCL.

Price Growth

ABCL (@Biotechnology) experienced а -1.05% price change this week, while LGND (@Biotechnology) price change was +6.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

ABCL is expected to report earnings on Nov 09, 2026.

LGND is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ABCL
Daily Signal:
Gain/Loss:
LGND
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

ABCL and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABCL has been loosely correlated with RXRX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABCL jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABCL
1D Price
Change %
ABCL100%
+4.53%
RXRX - ABCL
57%
Loosely correlated
-0.55%
CRSP - ABCL
56%
Loosely correlated
+1.24%
ABSI - ABCL
56%
Loosely correlated
+10.69%
VCYT - ABCL
56%
Loosely correlated
+3.19%
AXON - ABCL
51%
Loosely correlated
+2.54%
More

LGND and

Correlation & Price change

A.I.dvisor indicates that over the last year, LGND has been loosely correlated with AXON. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if LGND jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LGND
1D Price
Change %
LGND100%
+2.73%
AXON - LGND
49%
Loosely correlated
+2.54%
VCYT - LGND
41%
Loosely correlated
+3.19%
TVTX - LGND
41%
Loosely correlated
+0.54%
ABCL - LGND
37%
Loosely correlated
+4.53%
TRDA - LGND
36%
Loosely correlated
-6.81%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AMKL4.490.40
+9.78%
Defiance Daily Target 2X Long AMKR ETF (AMKL)
AIFD50.570.96
+1.93%
TCW Artificial Intelligence ETF (AIFD)
PABU79.680.54
+0.68%
iShares Paris-Aligned Climate Optimized MSCI USA ETF (PABU)
THEQ30.500.15
+0.50%
T. Rowe Price Hedged Equity ETF
GXC82.99-1.13
-1.35%
State Street SPDR S&P China ETF (GXC)